Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Prac
by from Morbidity and Mortality Weekly Report (MMWR) on (#4W32P)
Pneumococcal conjugate vaccine use in children has led to sharp declines in pneumococcal disease among adults and children.